Rivera S, Ghodssighassemabadi R, Auzac G, Brion T, Kirova Y, Racadot S, et al.
Lancet 2026; 407: 976-987.
Some 1221 women were included, and the 3-week radiotherapy was found to be non-inferior to 5-week radiotherapy with regards to arm lymphoedema risk (hazard ratio 1.09, 95 per cent confidence interval 0.79 to 1.31). Grade 3 or worse adverse event rates were similar between groups.
Comment: 3-week radiotherapy was non-inferior to 5-week treatment in lymphoedema risk, with comparable safety.
